Back

The expanding role of semaglutide in cardiovascular disease and its the effect on blood pressure

1 September 2024 (15:00 - 15:50)
Organised by: Logo
Congress Presentation Part of: Hypertension management: drugs Pharmacotherapy ESC Professional Premium Access ESC Congress 2024 European Society of Cardiology

About the speaker

Photo
Doctor Cormac Kennedy

Trinity College Dublin, Dublin (Ireland)

7 More presentations in this session

Presentation thumbnail
Systolic plood pressure response to ASi BI 690517 with and without empagliflozin in CKD
Professor P. Rossing (Herlev, DK)
Abstract Slides Video
Presentation thumbnail
Adherence to anti-hypertensive therapy with perindopril-based single-pill versus free-pill combinations: a 10-year real-world analysis in Italy
Associate Professor A. Vintila (Bucharest, RO)
Abstract Slides Video
Presentation thumbnail
Real-world analysis exploring the association between anti-hypertensive therapy with perindopril-based single-pill combinations (SPC) and cardiovascular outcomes and all-cause mortality in Italy
Doctor S. Masi (Pisa, IT) Associate Professor J. Wolf (Gdansk, PL)
Abstract Slides Video
Presentation thumbnail
Injectable angiotensinogen inhibition therapy for hypertension: a systematic review and meta-analysis
Doctor A. Yadav (New Delhi, IN)
Abstract Slides Video
Presentation thumbnail
A higher adherence to perindopril-based anti-hypertensive therapy is associated with a reduced risk of cardiovascular outcomes and all-cause mortality in real clinical practice in Italy
Doctor S. Masi (Pisa, IT)
Abstract Slides Video

Access the full session

Session thumbnail
Hypertension management: drugs

The Event

Event poster

ESC Congress 2024

1 September 2024 15:00 CET
You may be interested in
thumbnail
Congress Presentation
Semaglutide for the treatment of resistant hypertension
thumbnail
Congress Session
Late-Breaking Clinical Science: cardiometabolic medicine
thumbnail
Congress Presentation
Exploratory mediation analysis of the effect of semaglutide on cardiovascular outcomes in people with overweight or obesity in the SELECT randomised trial

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources